Data supplement to Valuck et al. Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study. Br J Psychiatry doi: 10.1192/bjp.bp.114.150839

Table DS1 Duloxetine-Venlafaxine Comparison: Demographics and Comorbidities Before and After Propensity Score Matching

	Duloxetine Unmatched n (%)	Venlafaxine Unmatched n (%)	Duloxetine Matched n (%)	Venlafaxine Matched n (%)
Total N	3028	5538	2629	5493
Demographic/Patient Char	acteristics			
Age at Index Date (mean, median)	43.11,44.00	41.06,42.00	42.53,43.00	41.02,42.00
Range (minimum, maximum)	(18-98)	(18-98)	(18-97)	(18-98)
Gender (female)	2017 (66.61%)	3744 (67.61%)	1736 (66.03%)	3714 (67.61%)
Medicaid Status	16 (0.53%)	66 (1.19%)	16 (0.61%)	59 (1.07%)
Region				
East	654 (21.60%)	1279 (23.09%)	557 (21.19%)	1277 (23.25%)
Midwest	1199 (39.60%)	2476 (44.71%)	1112 (42.30%)	2452 (44.64%)
South	975 (32.20%)	1387 (25.05%)	778 (29.59%)	1378 (25.09%)
West	200 (6.61%)	396 (7.15%)	182 (6.92%)	386 (7.03%)
Comorbidities				
CDI Score ^a (mean, median)	3.12,3.00	2.38,2.00	3.09,3.00	2.36,2.00
Range (minimum, maximum)	(0-19)	(0-21)	(0-18)	(0-21)
Charlson Comorbidity Score (mean, median)	0.85,0.00	0.63,0.00	0.79,0.00	0.62,0.00
Range (minimum, maximum)	(0-10)	(0-9)	(0-10)	(0-9)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	28 (0.51%)	9 (0.34%)	26 (0.47%)
Schizophrenia	3 (0.10%)	4 (0.07%)	3 (0.11%)	3 (0.05%)
Psychotic Disorder	21 (0.69%)	29 (0.52%)	20 (0.76%)	28 (0.51%)
Anxiety Spectrum Disorder	202 (6.67%)	399 (7.20%)	176 (6.69%)	393 (7.15%)
ADHD	16 (0.53%)	28 (0.51%)	12 (0.46%)	28 (0.51%)
Substance Use Disorder	140 (4.62%)	187 (3.38%)	114 (4.34%)	183 (3.33%)
Other Mental Health Disorder	117 (3.86%)	194 (3.50%)	97 (3.69%)	190 (3.46%)
No. of Mental Health Disorders (mean, median)	0.17,0.00	0.16,0.00	0.16,0.00	0.15,0.00
Range (minimum, maximum)	(0-4)	(0-5)	(0-4)	(0-5)
Terminal Diagnosis (HIV or malignant neoplasm)	84 (2.77%)	154 (2.78%)	69 (2.62%)	152 (2.77%)

Smoking	12 (0.40%)	16 (0.29%)	8 (0.30%)	16 (0.29%)
Seizure Disorder	24 (0.79%)	32 (0.58%)	22 (0.84%)	30 (0.55%)
Chronic Pain	16 (0.53%)	2 (0.04%)	5 (0.19%)	2 (0.04%)
Headaches (including migraine)	252 (8.32%)	339 (6.12%)	199 (7.57%)	334 (6.08%)
Stress Urinary Incontinence	18 (0.59%)	21 (0.38%)	14 (0.53%)	21 (0.38%)
Fibromyalgia	170 (5.61%)	169 (3.05%)	120 (4.56%)	164 (2.99%)
Diabetic Neuropathy	122 (4.03%)	92 (1.66%)	89 (3.39%)	89 (1.62%)
Low Back Pain / Back Pain	449 (14.83%)	535 (9.66%)	348 (13.24%)	530 (9.65%)

a. CDI score = Children's depression inventory score

Table DS2 Duloxetine-SSRI Comparison: Demographics and Comorbidities Before and After Propensity Score Matching

Range (minimum, (18-98) (18-98) (18-97) (18-97) Gender (female) 2017 (66.61%) 49.062 (66.17%) 2000 (66.64%) 6007 (67 Medicaid Status 16 (0.53%) 1436 (1.94%) 16 (0.53%) 93 (1.0 Region East 654 (21.60%) 14,788 (19.94%) 646 (21.53%) 1924 (21.60%) Midwest 1199 (39.60%) 37,586 (50.69%) 1195 (39.82%) 3522 (39.80%) South 975 (32.20%) 13,266 (17.89%) 961 (32.02%) 2669 (32.20%) West 200 (6.61%) 8509 (11.48%) 199 (6.63%) 638 (7.80%) Comorbidities CDI Score* (mean, median) 3.12,3.00 3.19,3.00 3.10,3.00 3.08,7. Range (minimum, (0-19) (1-21) (0-19) (1-64) Charison Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81,0.00 Range (minimum, (0-10) (0-14) (0-10) (0-70) (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%		Duloxetine Unmatched n (%)	SSRI ^a Unmatched n (%)	Duloxetine Matched n (%)	SSRI ^a Matched n(%)
Age at Index Date (mean, Range (minimum, (18-98)) 43.11,44.00 (18-98) 40.27,40.00 (18-98) 43.01,44.00 (18-97) 43.43,43,43,43,43,43,43,43,43,43,43,43,43,4	Total N	3028	74,149	3001	8953
Range (minimum, (18-98) (18-98) (18-97) (18-97) Gender (female) 2017 (66.61%) 49.062 (66.17%) 2000 (66.64%) 6007 (67.76) Medicaid Status 16 (0.53%) 1436 (1.94%) 16 (0.53%) 93 (1.0 Region East 654 (21.60%) 14,788 (19.94%) 646 (21.53%) 1924 (21.60%) Midwest 1199 (39.60%) 37,586 (50.69%) 1195 (39.82%) 3522 (39.20%) South 975 (32.20%) 13,266 (17.89%) 961 (32.02%) 2869 (32.20%) West 200 (6.61%) 8509 (11.48%) 199 (6.63%) 638 (7.20%) Comorbidities CDI Score* (mean, median) 3.12,3.00 3.19,3.00 3.10,3.00 3.08,7. Range (minimum, (0-19) (1-21) (0-19) (1-64) Charjson Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81,0.00 Range (minimum, (0-10) (0-14) (0-10) (0-20) Prior Depression 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) <td>Demographic/Patient Charac</td> <td>cteristics</td> <td></td> <td></td> <td></td>	Demographic/Patient Charac	cteristics			
Gender (female) 2017 (66.61%) 49,062 (66.17%) 2000 (66.64%) 6007 (67.67) Medicaid Status 16 (0.53%) 1436 (1.94%) 16 (0.53%) 93 (1.07) Region Fast 654 (21.60%) 14,788 (19.94%) 646 (21.53%) 1924 (21.60%) Midwest 1199 (39.60%) 37,586 (50.69%) 1195 (39.82%) 3522 (39.60%) South 975 (32.20%) 13,266 (17.89%) 961 (32.02%) 2869 (32.20%) West 200 (6.61%) 8509 (11.48%) 199 (6.63%) 638 (7.63%) Comorbidities CDI Score* (mean, median) 3.12,3.00 3.19,3.00 3.10,3.00 3.08,7.00 Chaison Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81,6.00 Range (minimum, (0-19) (1-21) (0-19) (1-21) Chaison Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81,6.00 Range (minimum, (0-19) (0-14) (0-10) (0-10) Chaisophrenia 3 (0.10%) 2 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)	Age at Index Date (mean,	43.11,44.00	40.27,40.00	43.01,44.00	43.43,44.00
Medicaid Status 16 (0.53%) 1436 (1.94%) 16 (0.53%) 93 (1.0 Region East 654 (21.60%) 14,788 (19.94%) 646 (21.53%) 1924 (21.53%) Midwest 1199 (39.60%) 37,586 (50.69%) 1195 (39.82%) 3522 (39.82%) South 975 (32.20%) 13,266 (17.89%) 961 (32.02%) 2869 (32.2%) West 200 (6.61%) 8509 (11.48%) 199 (6.63%) 638 (7.2%) Comorbidities 0.000 3.19,3.00 3.10,3.00 3.08,8.7 CDI Score³ (mean, median) 3.12,3.00 3.19,3.00 3.10,3.00 3.08,8.7 Range (minimum, (0-19) (1-21) (0-19) (1-21) Charison Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81,8.8 Range (minimum, (0-10) (0-14) (0-10) (0-0 Prior Depression 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 1 (0.00%) 1 (0.00%) 1 (0.00%) 1 (0.00%) 1 (0.00	Range (minimum,	(18-98)	(18-98)	(18-97)	(18-98)
Region	Gender (female)	2017 (66.61%)	49,062 (66.17%)	2000 (66.64%)	6007 (67.09%)
East Midwest Midwest Midwest South Midwest South Midwest South Midwest	Medicaid Status	16 (0.53%)	1436 (1.94%)	16 (0.53%)	93 (1.04%)
Midwest South 1199 (39.60%) 37,586 (50.69%) 1195 (39.82%) 3522 (39.85 (32.20%)) 3522 (39.85 (32.20%)) 37,586 (50.69%) 1195 (39.82%) 3522 (39.86 (32.20%)) 2869 (32.20%) 2860 (32.20%) 2860 (32.20	Region				
Midwest South 1199 (39.60%) 37,586 (50.69%) 1195 (39.82%) 3522 (39.85 outh 975 (32.20%) 13,266 (17.89%) 961 (32.02%) 2869 (32.20%) 2869 (32.20%) 2869 (32.20%) 2869 (32.20%) 2869 (32.20%) 2869 (32.20%) 2859 (11.48%) 199 (6.63%) 638 (7.20%) 2869 (32.20%) 2869 (32.20%) 2859 (11.48%) 199 (6.63%) 638 (7.20%) 2869 (32.20%) 2859 (11.48%) 199 (6.63%) 638 (7.20%) 2869 (32.20%) 30.00 3.10,3.00 3.08, 7.20% 3.10,3.00 3.10,3.00 3.08, 7.20% 3.10,3.00 3.10,3.00 3.08, 7.20% 3.10,3.00 3.08, 7.20% 3.00, 00 3.10,3.00 3.08, 00 3.00, 00 3.00, 00 3.00, 00 3.00, 00 3.00, 00 3.00, 00 3.00, 00 0.00, 00 <t< td=""><td>East</td><td>654 (21.60%)</td><td>14,788 (19.94%)</td><td>646 (21.53%)</td><td>1924 (21.49%)</td></t<>	East	654 (21.60%)	14,788 (19.94%)	646 (21.53%)	1924 (21.49%)
West 200 (6.61%) 8509 (11.48%) 199 (6.63%) 638 (7. Comorbidities CDI Score³ (mean, median) 3.12,3.00 3.19,3.00 3.10,3.00 3.00,3.00 Range (minimum, (0-19) (1-21) (0-19) (1-21) Charlson Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81,0.00 Range (minimum, (0-10) (0-14) (0-10) (0-10) Prior Depression 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) Bipolar Disorder/by proxy 9 (0.30%) 201 (0.27%) 9 (0.30%) 18 (0.20%) Schizophrenia 3 (0.10%) 25 (0.03%) 3 (0.10%) 8 (0.00%) Psychotic Disorder 21 (0.69%) 426 (0.57%) 21 (0.70%) 56 (0.64%) Anxiety Spectrum Disorder 202 (6.67%) 4,099 (5.53%) 201 (6.70%) 59 (6.06%) ADHD 16 (0.53%) 337 (0.45%) 16 (0.53%) 45 (0.5 Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.3 Other Mental Heal	Midwest		,		3522 (39.34%)
Comorbidities CDI Score³ (mean, median) 3.12,3.00 3.19,3.00 3.10,3.00 3.08, Range (minimum, (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-21) (0-19) (1-27) (1-20) (0-20) 0.83,0.00 0.81,1 (0-20) 0.83,0.00 0.81,1 (0-20) 0.82,0.00 0.83,0.00 0.81,1 (0-20) 0.00 <td< td=""><td>South</td><td>975 (32.20%)</td><td>13,266 (17.89%)</td><td>961 (32.02%)</td><td>2869 (32.05%)</td></td<>	South	975 (32.20%)	13,266 (17.89%)	961 (32.02%)	2869 (32.05%)
CDI Score® (mean, median) 3.12,3.00 3.19,3.00 3.10,3.00 3.08, Range (minimum, (0-19) (1-21) (0-19) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10) (0-10	West	200 (6.61%)	8509 (11.48%)	199 (6.63%)	638 (7.13%)
Range (minimum, (0-19) (1-21) (0-19) (1-21) Charlson Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81, and one of the provision of	Comorbidities				
Charlson Comorbidity Score 0.85,0.00 0.67,0.00 0.83,0.00 0.81,0.00 Range (minimum, (0-10) (0-14) (0-10) (0-14) (0-10) (0-10) Prior Depression 0 (0.00%) 0			The state of the s		3.08,2.00
Range (minimum, (0-10) (0-14) (0-10) (0-10) Prior Depression 0 (0.00%) 18 (0.20%) 20 (0.00%)	•	` ,	` ,	, ,	(1-18)
Prior Depression 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) Bipolar Disorder/by proxy 9 (0.30%) 201 (0.27%) 9 (0.30%) 18 (0.20%) Schizophrenia 3 (0.10%) 25 (0.03%) 3 (0.10%) 8 (0.00%) Psychotic Disorder 21 (0.69%) 426 (0.57%) 21 (0.70%) 56 (0.60%) Anxiety Spectrum Disorder 202 (6.67%) 4,099 (5.53%) 201 (6.70%) 599 (6.40%) ADHD 16 (0.53%) 337 (0.45%) 16 (0.53%) 45 (0.50%) Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.30%) Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.30%) No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.40.25%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.30.25%)		•	•	0.83,0.00	0.81,0.00
Bipolar Disorder/by proxy 9 (0.30%) 201 (0.27%) 9 (0.30%) 18 (0.25%) Schizophrenia 3 (0.10%) 25 (0.03%) 3 (0.10%) 8 (0.05%) Psychotic Disorder 21 (0.69%) 426 (0.57%) 21 (0.70%) 56 (0.65%) Anxiety Spectrum Disorder 202 (6.67%) 4,099 (5.53%) 201 (6.70%) 599 (6.05%) ADHD 16 (0.53%) 337 (0.45%) 16 (0.53%) 45 (0.55%) Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.35) Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.35) No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.50%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.55%) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.65%) Chr	Range (minimum,	(0-10)	(0-14)	(0-10)	(0-14)
Schizophrenia 3 (0.10%) 25 (0.03%) 3 (0.10%) 8 (0.00) Psychotic Disorder 21 (0.69%) 426 (0.57%) 21 (0.70%) 56 (0.60) Anxiety Spectrum Disorder 202 (6.67%) 4,099 (5.53%) 201 (6.70%) 599 (6.60) ADHD 16 (0.53%) 337 (0.45%) 16 (0.53%) 45 (0.50) Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.50) Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.50) No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.50) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.30) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.60) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.50) Headaches (including <td>Prior Depression</td> <td>0 (0.00%)</td> <td>0 (0.00%)</td> <td>0 (0.00%)</td> <td>0 (0.00%)</td>	Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Psychotic Disorder 21 (0.69%) 426 (0.57%) 21 (0.70%) 56 (0.60%) Anxiety Spectrum Disorder 202 (6.67%) 4,099 (5.53%) 201 (6.70%) 599 (6.00%) ADHD 16 (0.53%) 337 (0.45%) 16 (0.53%) 45 (0.50%) Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.30%) Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.30%) No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.30%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.30%) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.60%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.40%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.80%)	Bipolar Disorder/by proxy	9 (0.30%)	201 (0.27%)	9 (0.30%)	18 (0.20%)
Anxiety Spectrum Disorder 202 (6.67%) 4,099 (5.53%) 201 (6.70%) 599 (6.4 ADHD 16 (0.53%) 337 (0.45%) 16 (0.53%) 45 (0.5 Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.5 Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.5 No. of Mental Health Disorder 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 0.15,0.00 No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 0.15,0.00 No. of Mental Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.5 Noking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.3 Noking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.3 Noking 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.60%) Noking 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.5 Noking 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.5 Noking 252 (8.32%) 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.5 Noking 252 (8.32%) 1365 (1.84%) 117 (3.90%) 293 (3.5 Noking 252 (8.5 Noking 252 (8.5 Noking 252 (8.	Schizophrenia	3 (0.10%)	25 (0.03%)	3 (0.10%)	8 (0.09%)
ADHD 16 (0.53%) 337 (0.45%) 16 (0.53%) 45 (0.53%) Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.30) Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.30) No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0 Range (minimum, (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-4) (0-5) (0-6		21 (0.69%)	426 (0.57%)	21 (0.70%)	56 (0.63%)
Substance Use Disorder 140 (4.62%) 2724 (3.67%) 136 (4.53%) 353 (3.33) Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.33) No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.40.24%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.33) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.60.24%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.60.24%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.40.24%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.60.24%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.30.24%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.30.24%)				, ,	599 (6.69%)
Other Mental Health Disorder 117 (3.86%) 2342 (3.16%) 113 (3.77%) 302 (3.38%) No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.40.24%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.30.24%) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.60.24%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.40.24%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.40.24%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.80.24%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.30.24%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.30.24%)					45 (0.50%)
No. of Mental Health 0.17,0.00 0.14,0.00 0.16,0.00 0.15,0.00 Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.40.24%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.30.24%) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.60.24%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.20.24%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.40.24%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.50.24%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.30.24%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.30.24%)					353 (3.94%)
Range (minimum, (0-4) (0-5) (0-4) (0-5) Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.57%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.37%) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.67%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.77%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.47%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.57%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.57%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.57%)					302 (3.37%)
Terminal Diagnosis (HIV or malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.57%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.37%) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.67%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.77%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.47%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.57%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.57%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.57%)		*	•	•	0.15,0.00
malignant neoplasm) 84 (2.77%) 1765 (2.38%) 79 (2.63%) 224 (2.88%) Smoking 12 (0.40%) 255 (0.34%) 12 (0.40%) 31 (0.38%) Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.68%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.78%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.88%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.58%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.88%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.88%)	\	(0-4)	(0-5)	(0-4)	(0-5)
Seizure Disorder 24 (0.79%) 505 (0.68%) 23 (0.77%) 59 (0.68%) Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.78%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.48%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.58%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.38%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.38%)	o v	84 (2.77%)	1765 (2.38%)	79 (2.63%)	224 (2.50%)
Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.53%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.03%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.53%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.33%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.33%)	Smoking	12 (0.40%)	255 (0.34%)	12 (0.40%)	31 (0.35%)
Chronic Pain 16 (0.53%) 47 (0.06%) 10 (0.33%) 15 (0.53%) Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.03%) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.53%) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.33%) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.33%)	Seizure Disorder	24 (0.79%)	505 (0.68%)	23 (0.77%)	59 (0.66%)
Headaches (including 252 (8.32%) 4,691 (6.33%) 247 (8.23%) 688 (7.024) Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.524) Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.524) Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.524)				, ,	15 (0.17%)
Stress Urinary Incontinence 18 (0.59%) 265 (0.36%) 18 (0.60%) 46 (0.5 (0.5 (0.5 (0.36 (0.5 (0.5 (0.5 (0.5 (0.5 (0.5 (0.5 (0.5	Headaches (including				688 (7.68%)
Fibromyalgia 170 (5.61%) 1791 (2.42%) 161 (5.36%) 392 (4.3.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.	Stress Urinary Incontinence	,	,	, ,	46 (0.51%)
Diabetic Neuropathy 122 (4.03%) 1365 (1.84%) 117 (3.90%) 293 (3.3.41)	•	, ,	,	, ,	392 (4.38%)
		,	,	` ,	293 (3.27%)
Low Back Pain / Back Pain 449 (14.83%) 6336 (8.54%) 436 (14.53%) 1139 (12.	, ,	,	` ,	` ,	1139 (12.72%)

a. Abbreviation: SSRI = Selective serotonin reuptake inhibitor, CDI Score = Children's Depression Inventory score.

Table DS3 Duloxetine-TCA^a Comparison: Demographics and Comorbidities Before and After Propensity Score Matching

	Duloxetine Unmatched n (%)	TCA ^a Unmatched n (%)	Duloxetine Matched n (%)	TCA ^a Matched n (%)
Total N	3028	1146	1064	1064
	Demographic/P	atient Characteristic	s	
Age at Index Date (mean,	43.11,44.00	44.32,45.00	42.08,43.00	44.50,45.00
Range (minimum,	(18-98)	(18-98)	(18-81)	(18-98)
Gender (female)	2017 (66.61%)	772 (67.36%)	715 (67.20%)	722 (67.86%)
Medicaid Status	16 (0.53%)	31 (2.71%)	11 (1.03%)	23 (2.16%)
Region				
East	654 (21.60%)	243 (21.20%)	239 (22.46%)	233 (21.90%)
Midwest	1199 (39.60%)	511 (44.59%)	503 (47.27%)	467 (43.89%)
South	975 (32.20%)	269 (23.47%)	212 (19.92%)	261 (24.53%)
West	200 (6.61%)	123 (10.73%)	110 (10.34%)	103 (9.68%)
Comorbidities				
CDI Score (mean, median)	3.12,3.00	4.68,4.00	3.52,3.00	4.60,4.00
Range (minimum,	(0-19)	(2-18)	(0-16)	(2-18)
Charlson Comorbidity Score	0.85,0.00	0.92,1.00	0.85,0.00	0.91,1.00
Range (minimum,	(0-10)	(0-9)	(0-10)	(0-9)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	9 (0.79%)	4 (0.38%)	9 (0.85%)
Schizophrenia	3 (0.10%)	1 (0.09%)	1 (0.09%)	1 (0.09%)
Psychotic Disorder	21 (0.69%)	7 (0.61%)	9 (0.85%)	5 (0.47%)
Anxiety Spectrum Disorder	202 (6.67%)	62 (5.41%)	58 (5.45%)	55 (5.17%)
ADHD	16 (0.53%)	0 (0.00%)	4 (0.38%)	0 (0.00%)
Substance Use Disorder	140 (4.62%)	52 (4.54%)	44 (4.14%)	44 (4.14%)
Other Mental Health Disorder	117 (3.86%)	50 (4.36%)	43 (4.04%)	47 (4.42%)
No. of Mental Health Disorders	0.17,0.00	0.15,0.00	0.15,0.00	0.15,0.00
Range (minimum,	(0-4)	(0-4)	(0-3)	(0-2)
Terminal Diagnosis (HIV or malignant neoplasm)	84 (2.77%)	45 (3.93%)	33 (3.10%)	40 (3.76%)
Smoking	12 (0.40%)	5 (0.44%)	4 (0.38%)	4 (0.38%)
Seizure Disorder	24 (0.79%)	15 (1.31%)	13 (1.22%)	11 (1.03%)
Chronic Pain	16 (0.53%)	3 (0.26%)	2 (0.19%)	1 (0.09%)
Headaches (including	252 (8.32%)	179 (15.62%)	72 (6.77%)	172 (16.17%)
Stress Urinary Incontinence	18 (0.59%)	4 (0.35%)	5 (0.47%)	3 (0.28%)
Fibromyalgia	170 (5.61%)	64 (5.58%)	37 (3.48%)	60 (5.64%)
Diabetic Neuropathy	122 (4.03%)	51 (4.45%)	33 (3.10%)	48 (4.51%)
Low Back Pain / Back Pain	449 (14.83%)	177 (15.45%)	119 (11.18%)	163 (15.32%)

a. Abbreviation: TCA = Tricyclic antidepressant, CDI score = Children's Depression Inventory score.

Table DS4 Duloxetine-Multiple Antidepressant Comparison: Demographics and Comorbidities Before and After Propensity Score Matching

	Duloxetine Unmatched n (%)	Multiple AD ^a Unmatched n (%)	Duloxetine Matched n (%)	Multiple AD ^a Matched n (%)
Total N	3028	28,246	2948	8408
Demographic/Patient Cha	racteristics			
Age at Index Date (mean,	43.11,44.00	40.30,41.00	42.91,44.00	42.59,43.00
Range (minimum,	(18-98)	(18-98)	(18-97)	(18-98)
Gender (female)	2017 (66.61%)	18,491 (65.46%)	1961 (66.52%)	5480 (65.18%)
Medicaid Status	16 (0.53%)	693 (2.45%)	16 (0.54%)	99 (1.18%)
Region				
East	654 (21.60%)	5227 (18.51%)	642 (21.78%)	1720 (20.46%)
Midwest	1199 (39.60%)	14,824 (52.48%)	1188 (40.30%)	3427 (40.76%)
South	975 (32.20%)	5333 (18.88%)	922 (31.28%)	2749 (32.70%)
West	200 (6.61%)	2862 (10.13%)	196 (6.65%)	512 (6.09%)
Comorbidities				
CDI Score ^a (mean, median)	3.12,3.00	3.92,3.00	3.09,3.00	3.62,3.00
Range (minimum,	(0-19)	(0-20)	(0-19)	(0-19)
Charlson Comorbidity	0.85,0.00	0.78,0.00	0.83,0.00	0.86,0.00
Range (minimum,	(0-10)	(0-11)	(0-10)	(0-11)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	135 (0.48%)	9 (0.31%)	33 (0.39%)
Schizophrenia	3 (0.10%)	6 (0.02%)	3 (0.10%)	3 (0.04%)
Psychotic Disorder	21 (0.69%)	203 (0.72%)	20 (0.68%)	66 (0.78%)
Anxiety Spectrum Disorder	202 (6.67%)	1738 (6.15%)	200 (6.78%)	610 (7.25%)
ADHD	16 (0.53%)	127 (0.45%)	15 (0.51%)	37 (0.44%)
Substance Use Disorder	140 (4.62%)	1395 (4.94%)	136 (4.61%)	447 (5.32%)
Other Mental Health	117 (3.86%)	1102 (3.90%)	112 (3.80%)	364 (4.33%)
No. of Mental Health	0.17,0.00	0.17,0.00	0.17,0.00	0.18,0.00
Range (minimum, maximum)	(0-4)	(0-5)	(0-4)	(0-4)
Terminal Diagnosis (HIV or malignant	84 (2.77%)	661 (2.34%)	78 (2.65%)	225 (2.68%)
Smoking	12 (0.40%)	106 (0.38%)	12 (0.41%)	28 (0.33%)
Seizure Disorder	24 (0.79%)	164 (0.58%)	23 (0.78%)	55 (0.65%)
Chronic Pain	16 (0.53%)	15 (0.05%)	8 (0.27%)	8 (0.10%)
Headaches	,	, ,		, ,
(including migraine)	252 (8.32%)	2341 (8.29%)	235 (7.97%)	795 (9.46%)
Stress Urinary Incontinence	18 (0.59%)	113 (0.40%)	16 (0.54%)	56 (0.67%)
Fibromyalgia	170 (5.61%)	953 (3.37%)	151 (5.12%)	475 (5.65%)
Diabetic Neuropathy	122 (4.03%)	679 (2.40%)	114 (3.87%)	328 (3.90%)
Low Back Pain / Back Pain	449 (14.83%)	3301 (11.69%)	420 (14.25%)	1410 (16.77%)

a. Abbreviation: AD = antidepressant, CDI score = Children's Depression Inventory score.

Table DS5 Duloxetine-Depressed Untreated (No Antidepressant, AD) Comparison: Demographics and Comorbidities Before and After Propensity Score Matching

	Duloxetine Unmatched n (%)	No AD ^a Unmatched n (%)	Duloxetine Matched n (%)	No AD ^a Matched n (%)
Total N	3028	255,209	237	564
Demographic/Patient Chara	cteristics			
Age at Index Date (mean,	43.11,44.00	41.94,43.00	44.01,44.00	47.07,48.00
Range (minimum,	(18-98)	(18-98)	(18-81)	(18-98)
Gender (female)	2017 (66.61%)	165,894 (65.00%)	168 (70.89%)	373 (66.13%)
Medicaid Status	16 (0.53%)	5,438 (2.13%)	4 (1.69%)	4 (0.71%)
Region				
East	654 (21.60%)	75,765 (29.69%)	41 (17.30%)	143 (25.35%)
Midwest	1199 (39.60%)	96,612 (37.86%)	108 (45.57%)	151 (26.77%)
South	975 (32.20%)	61,364 (24.04%)	57 (24.05%)	241 (42.73%)
West	200 (6.61%)	21,468 (8.41%)	31 (13.08%)	29 (5.14%)
Comorbidities				
CDI Score ^a (mean, median)	3.12,3.00	1.28,0.00	4.35,4.00	1.92,1.00
Range (minimum,	(0-19)	(0-21)	(0-16)	(0-17)
Charlson Comorbidity Score	0.85,0.00	0.82,0.00	1.00,1.00	1.57,1.00
Range (minimum,	(0-10)	(0-17)	(0-10)	(0-11)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	1493 (0.59%)	1 (0.42%)	5 (0.89%)
Schizophrenia	3 (0.10%)	236 (0.09%)	0 (0.00%)	5 (0.89%)
Psychotic Disorder	21 (0.69%)	1968 (0.77%)	6 (2.53%)	9 (1.60%)
Anxiety Spectrum Disorder	202 (6.67%)	16,458 (6.45%)	13 (5.49%)	65 (11.52%)
ADHD	16 (0.53%)	1452 (0.57%)	0 (0.00%)	4 (0.71%)
Substance Use Disorder	140 (4.62%)	10,711 (4.20%)	7 (2.95%)	48 (8.51%)
Other Mental Health Disorder	117 (3.86%)	10,676 (4.18%)	9 (3.80%)	40 (7.09%)
No. of Mental Health	0.17,0.00	0.17,0.00	0.15,0.00	0.30,0.00
Range (minimum,	(0-4)	(0-6)	(0-2)	(0-3)
Terminal Diagnosis (HIV or malignant neoplasm)	84 (2.77%)	8061 (3.16%)	5 (2.11%)	23 (4.08%)
Smoking	12 (0.40%)	931 (0.36%)	0 (0.00%)	6 (1.06%)
Seizure Disorder	24 (0.79%)	2395 (0.94%)	1 (0.42%)	14 (2.48%)
Chronic Pain	16 (0.53%)	325 (0.13%)	1 (0.42%)	42 (7.45%)
Headaches (including	252 (8.32%)	18,943 (7.42%)	17 (7.17%)	72 (12.77%)
Stress Urinary Incontinence	18 (0.59%)	1177 (0.46%)	1 (0.42%)	8 (1.42%)
Fibromyalgia	170 (5.61%)	8171 (3.20%)	10 (4.22%)	84 (14.89%)
Diabetic Neuropathy	122 (4.03%)	6535 (2.56%)	15 (6.33%)	52 (9.22%)
Low Back Pain / Back Pain	449 (14.83%)	25,859 (10.13%)	24 (10.13%)	176 (31.21%)

a. Abbreviation: AD = antidepressant, CDI score = Children's Depression Inventory score.

Table DS6 Comparison of All Study Cohorts: Demographics and Comorbidities after Propensity Score Matching

	Duloxetine n (%)	Venlafaxine n (%)	SSRI ^a N (%)	TCA ^a n (%)	Multiple n (%)	Untreated Depression n (%)	GPS ^a n (%)
Total N	3009	5493	8953	1064	8408	564	27,476
Demographic/Patient Characteristi	ics						
Age at Index Date (mean, median)	43.04,44.00	41.02,42.00	43.43,44.00	44.50,45.00	42.59,43.00	47.07,48.00	43.04,44.00
Range (minimum, maximum)	(18-97)	(18-98)	(18-98)	(18-98)	(18-98)	(18-98)	(18-98)
Gender (female)	2005 (66.63%)	3714 (67.61%)	6007 (67.09%)	722 (67.86%)	5480 (65.18%)	373 (66.13%)	17,950 (65.33%)
Medicaid Status	16 (0.53%)	59 (1.07%)	93 (1.04%)	23 (2.16%)	99 (1.18%)	4 (0.71%)	306 (1.11%)
Region							
East	648 (21.54%)	1277 (23.25%)	1924 (21.49%)	233 (21.90%)	1720 (20.46%)	143 (25.35%)	5968 (21.72%)
Midwest	1196 (39.75%)	2452 (44.64%)	3522 (39.34%)	467 (43.89%)	3427 (40.76%)	151 (26.77%)	10,718 (39.01%)
South	966 (32.10%)	1378 (25.09%)	2869 (32.05%)	261 (24.53%)	2749 (32.70%)	241 (42.73%)	8968 (32.64%)
West	199 (6.61%)	386 (7.03%)	638 (7.13%)	103 (9.68%)	512 (6.09%)	29 (5.14%)	1822 (6.63%)
Comorbidities (6 mo prior to index	date)						
CDI Score ^a (mean, median)	3.11,3.00	2.36,2.00	3.08,2.00	4.60,4.00	3.62,3.00	1.92,1.00	1.65,1.00
Range (minimum, maximum)	(0-19)	(0-21)	(1-18)	(2-18)	(0-19)	(0-17)	(0-18)
Charlson Comorbidity Score (mean, median)	0.84,0.00	0.62,0.00	0.81,0.00	0.91,1.00	0.86,0.00	1.57,1.00	0.00,0.00
Range (minimum, maximum)	(0-10)	(0-9)	(0-14)	(0-9)	(0-11)	(0-11)	(0-0)
Prior Depression	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bipolar Disorder/by proxy	9 (0.30%)	26 (0.47%)	18 (0.20%)	9 (0.85%)	33 (0.39%)	5 (0.89%)	136 (0.49%)
Schizophrenia	3 (0.10%)	3 (0.05%)	8 (0.09%)	1 (0.09%)	3 (0.04%)	5 (0.89%)	16 (0.06%)
Psychotic Disorder	21 (0.70%)	28 (0.51%)	56 (0.63%)	5 (0.47%)	66 (0.78%)	9 (1.60%)	72 (0.26%)
Anxiety Spectrum Disorder	202 (6.71%)	393 (7.15%)	599 (6.69%)	55 (5.17%)	610 (7.25%)	65 (11.52%)	635 (2.31%)
ADHD	16 (0.53%)	28 (0.51%)	45 (0.50%)	0 (0.00%)	37 (0.44%)	4 (0.71%)	88 (0.32%)
Substance Use Disorder	140 (4.65%)	183 (3.33%)	353 (3.94%)	44 (4.14%)	447 (5.32%)	48 (8.51%)	515 (1.87%)
Other Mental Health Disorder	116 (3.86%)	190 (3.46%)	302 (3.37%)	47 (4.42%)	364 (4.33%)	40 (7.09%)	675 (2.46%)
No. of Mental Health Disorders (mean, median)	0.17,0.00	0.15,0.00	0.15,0.00	0.15,0.00	0.18,0.00	0.30,0.00	0.08,0.00
Range (minimum, maximum)	(0-4)	(0-5)	(0-5)	(0-2)	(0-4)	(0-3)	(0-6)
Terminal Diagnosis (HIV or malignant neoplasm)	80 (2.66%)	152 (2.77%)	224 (2.50%)	40 (3.76%)	225 (2.68%)	23 (4.08%)	574 (2.09%)
Smoking	12 (0.40%)	16 (0.29%)	31 (0.35%)	4 (0.38%)	28 (0.33%)	6 (1.06%)	52 (0.19%)
Seizure Disorder	23 (0.76%)	30 (0.55%)	59 (0.66%)	11 (1.03%)	55 (0.65%)	14 (2.48%)	113 (0.41%)
Chronic Pain	10 (0.33%)	2 (0.04%)	15 (0.17%)	1 (0.09%)	8 (0.10%)	42 (7.45%)	15 (0.05%)
Headaches (including migraine)	248 (8.24%)	334 (6.08%)	688 (7.68%)	172 (16.17%)	795 (9.46%)	72 (12.77%)	1148 (4.18%)
Stress Urinary Incontinence	18 (0.60%)	21 (0.38%)	46 (0.51%)	3 (0.28%)	56 (0.67%)	8 (1.42%)	105 (0.38%)
Fibromyalgia	164 (5.45%)	164 (2.99%)	392 (4.38%)	60 (5.64%)	475 (5.65%)	84 (14.89%)	512 (1.86%)
Diabetic Neuropathy	118 (3.92%)	89 (1.62%)	293 (3.27%)	48 (4.51%)	328 (3.90%)	52 (9.22%)	418 (1.52%)

Low Back Pain / Back Pain 440 (14.62%) 530 (9.65%) 1139 (12.72%) 163 (15.32%) 1410 (16.77%) 176 (31.21%) 1709 (6.22%)

a. Abbreviations: GPS = Community-based general population sample, SSRI = Selective serotonin reuptake inhibitor, TCA = Tricyclic antidepressant, CDI score = Children's Depression score.

Table DS7 The Effect of Study Cohort (Drug or Drug Class) on Suicide Attempt Risk, Estimated Using Unadjusted and Adjusted Multivariate Cox PH Models of Time to Suicide Attempt

		Unadjusted Mo			Adjusted Mode	el	
	HR^a	95% CI ^a		HR^{a}	95% Cl ^a		
Study Group							
Duloxetine		Referent grou	qı		Referent group)	
Venlafaxine	0.90	0.51	1.57	1.01	0.57	1.77	
SSRI ^a	0.95	0.56	1.62	0.89	0.52	1.52	
TCA ^a	0.56	0.22	1.41	0.52	0.20	1.31	
Multiple AD ^a	3.57	2.21	5.77	3.11	1.92	5.04	
Depressed/No AD ^a	2.16	1.00	4.67	1.28	0.55	2.97	
GPS	0.12	0.07	0.23	0.17	0.09	0.32	
Demographics							
Female				0.95	0.76	1.19	
Age group							
Young adult (18-24 yrs.)				3.31	2.54	4.33	
Adult (25-64 yrs.)					Referent group)	
Older adult (65+ yrs.)				0.76	0.24	2.41	
Medicaid				1.77	1.07	2.93	
Region							
East					Referent group		
Midwest				2.23	1.83	4.36	
South				1.91	1.35	2.72	
West				2.83	1.83	4.36	
Comorbidities							
CDI score				1.04	0.99	1.08	
Depression				1.82	1.30	2.55	
Bipolar				2.75	1.97	3.85	
Schizophrenia				1.31	0.51	3.35	
Psychotic disorder				1.71	1.11	2.62	
Anxiety				1.07	0.82	1.41	
ADHD ^a				1.07	0.58	1.98	
Substance abuse			2.42	1.82	3.22		
Other mental health		2.04	1.59	2.60			
concern				2.04	1.59	2.00	
Chronic pain		4.39	1.88	10.25			
Headache				1.00	0.75	1.39	
Fibromyalgia				0.87	0.60	1.26	
Diabetic neuropathy				0.59	0.33	1.07	

a. Abbreviations: HR = Hazard ratio, 95% CI = 95% confidence interval, TCA = Tricyclic antidepressant, GPS = Community-based general population sample, AD = Antidepressant, CDI score = Children's depression inventory score, ADHD = Attention deficit hyperactivity disorder, SSRI = Selective serotonin reuptake inhibitor, ADHD = Attention Deficit Hyperactivity Disorder.